Doxazosin Tablet
Product Images NDC 71610-878

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-878). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0878 60)

Label for Doxazosin USP 8 mg tablets, oral dosage form, containing 90 tablets. The label includes storage instructions to keep between 20-25 degrees Celsius and to store in a controlled room temperature environment. It indicates the product is packaged by Aphena Pharma Solutions - Tennessee, LLC, with manufacturing by Apotex Inc. in Toronto, Ontario. The NDC is 71610-878-60. The label states RX Only and includes batch and lot number areas.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure of the active ingredient doxazosin, showing its molecular composition and arrangement, including aromatic rings, nitrogen atoms, and methoxy groups, consistent with the pharmaceutical compound doxazosin.*

FDA Label Image

Figure1.jpg (Figure1)

This image contains two line graphs comparing Doxazosin and placebo effects over 14 weeks. The left graph shows mean change in total symptom score from baseline, with Doxazosin demonstrating a greater symptom reduction than placebo. The right graph depicts mean increase in maximum urinary flow rate (mL/sec) from baseline, showing a higher flow rate increase for Doxazosin compared to placebo. Both graphs include statistical significance markers and sample sizes.*

FDA Label Image

Table3.jpg (Table3)

A chart summarizing effectiveness data from placebo-controlled clinical trials of Doxazosin. It compares symptom scores and maximum flow rate changes in three studies, showing mean baseline and mean change for placebo and Doxazosin at 4 mg and 8 mg doses. A bar graph illustrates maximum flow rate improvements in Study 2, highlighting greater increases with Doxazosin compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.